Patrick Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Patrick Tan has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Bin Tean Teh
Cancer and Stem Cell Biology Programme, Duke-NUS Medical School, Singapore 169857, Singapore
87 shared publications - Yunqiang Chu
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
80 shared publications - Micah A. Luftig
Department of Molecular Genetics and Microbiology, Duke University School of Medicine
75 shared publications - Hazel Xiaohui Ang
Department of Medicine Huddinge Karolinska Institute Huddinge Sweden
73 shared publications - Jacob P. Hoj
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA
73 shared publications - Kris C. Wood
Department of Pharmacology and Cancer Biology, Duke University, Durham, USA
73 shared publications
Latest Publications
- 5 November 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Pre‐emptive pharmacogenomics testing in clinical practice: A pilot implementation in Singapore
Aims: Pre‐emptive pharmacogenomics (PPGx) testing holds promise for optimizing drug therapy, but uptake remains limited in Asia. This pilot study aimed to assess the feasibility of PPGx uptake into clinical practice and its impact on prescribing in an Asian healthcare setting. Methods: A prospective, multicentre pilot study was conducted to pre‐emptively genotype 16 pharmacogenes. Results were integrated into electronic health records, alongside deployment of clinical decision support (CDS) tools for 31 drug–gene pairs. A pharmacogenomics drug information service and digital platforms were also developed. Results: All 2492 participants carried ≥1 actionable variant (median: 5, range: 1–11). Across four institutions within one cluster, 1046 out of 2238 (46.7%) patients were prescribed ≥1 drug with pharmacogenetic association, and of those, 460 (44%) had genotypes linked to undesirable drug responses. Among 285 interruptive CDS alerts, 69 (24.2%) led to prescription modifications. Acceptance was higher for new prescriptions (50.0% vs . 17.3%, p < 0.001), in outpatient settings (31.0% vs . 7.3%, p < 0.001) and among consultants (57.1% vs . other designations 5–27.3%, p < 0.001). The drug information service received 137 enquiries, while 471 and 151 patients accessed the app and web‐based platforms respectively. Conclusions: PPGx testing and genotype‐guided prescribing are feasible in Singapore. Widespread adoption requires leadership support, robust informatics infrastructure, clinician engagement and sustainable funding.
- 5 November 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Pre‐emptive pharmacogenomics testing in clinical practice: A pilot implementation in Singapore
Aims: Pre‐emptive pharmacogenomics (PPGx) testing holds promise for optimizing drug therapy, but uptake remains limited in Asia. This pilot study aimed to assess the feasibility of PPGx uptake into clinical practice and its impact on prescribing in an Asian healthcare setting. Methods: A prospective, multicentre pilot study was conducted to pre‐emptively genotype 16 pharmacogenes. Results were integrated into electronic health records, alongside deployment of clinical decision support (CDS) tools for 31 drug–gene pairs. A pharmacogenomics drug information service and digital platforms were also developed. Results: All 2492 participants carried ≥1 actionable variant (median: 5, range: 1–11). Across four institutions within one cluster, 1046 out of 2238 (46.7%) patients were prescribed ≥1 drug with pharmacogenetic association, and of those, 460 (44%) had genotypes linked to undesirable drug responses. Among 285 interruptive CDS alerts, 69 (24.2%) led to prescription modifications. Acceptance was higher for new prescriptions (50.0% vs . 17.3%, p < 0.001), in outpatient settings (31.0% vs . 7.3%, p < 0.001) and among consultants (57.1% vs . other designations 5–27.3%, p < 0.001). The drug information service received 137 enquiries, while 471 and 151 patients accessed the app and web‐based platforms respectively. Conclusions: PPGx testing and genotype‐guided prescribing are feasible in Singapore. Widespread adoption requires leadership support, robust informatics infrastructure, clinician engagement and sustainable funding.
- Open Access
- 2 November 2026
- Published by Springer Nature in Nature Communications
Single-cell pharmacogenomic landscapes of epigenetic therapy revealed by gastric cancer Perturb-seq
- 2 November 2026
- Published by Springer Nature in Nature Communications
Open AccessSingle-cell pharmacogenomic landscapes of epigenetic therapy revealed by gastric cancer Perturb-seq
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- Open Access
- 7 October 2026
- Published by Springer Nature in BMC Medicine
Implementing reproductive carrier screening to include diverse Asian populations: insights from Singapore
Background: As part of Singapore’s effort towards precision medicine tailored to Asian diversity, we describe the implementation of a nationwide reproductive carrier screening program. Using a customised 112-gene panel, targeting population-specific recessive genetic diseases, we outline the overall program design, and initial efforts of community and stakeholder engagement to inform culturally appropriate implementation. Methods: Participants receive culturally tailored online education regarding our reproductive screening program and are provided results with genetic counselling and reproductive options. Engagement with religious leaders indicated support for the program. Community and stakeholder perspectives were assessed through questionnaires. Results: Recruitment is nation-wide, and since initiation of our pilot phase in September 2024, 1,619 couples have registered interest, with 60% uptake of those deemed eligible. Among the 550 couples that have received results to date, six couples (1.0%) were identified to be at increased risk. Community questionnaire responses ( n = 1,002), involving couples who participated in the program as well as the general public, indicated interest was high (59%) across the cohort but awareness, intent to participate and implications for reproductive options differed by sociodemographic factors such as ancestry and religion. Healthcare professional respondents ( n = 113) acknowledged carrier screening will be routine in medical care, but report limited confidence and resources. Conclusions: These early program outcomes and community engagement are guiding the implementation of expanding population-based carrier screening in Singapore, contingent on addressing practical challenges through equitable outreach and professional training.
- 7 October 2026
- Published by Springer Nature in BMC Medicine
Open AccessImplementing reproductive carrier screening to include diverse Asian populations: insights from Singapore
Background: As part of Singapore’s effort towards precision medicine tailored to Asian diversity, we describe the implementation of a nationwide reproductive carrier screening program. Using a customised 112-gene panel, targeting population-specific recessive genetic diseases, we outline the overall program design, and initial efforts of community and stakeholder engagement to inform culturally appropriate implementation. Methods: Participants receive culturally tailored online education regarding our reproductive screening program and are provided results with genetic counselling and reproductive options. Engagement with religious leaders indicated support for the program. Community and stakeholder perspectives were assessed through questionnaires. Results: Recruitment is nation-wide, and since initiation of our pilot phase in September 2024, 1,619 couples have registered interest, with 60% uptake of those deemed eligible. Among the 550 couples that have received results to date, six couples (1.0%) were identified to be at increased risk. Community questionnaire responses ( n = 1,002), involving couples who participated in the program as well as the general public, indicated interest was high (59%) across the cohort but awareness, intent to participate and implications for reproductive options differed by sociodemographic factors such as ancestry and religion. Healthcare professional respondents ( n = 113) acknowledged carrier screening will be routine in medical care, but report limited confidence and resources. Conclusions: These early program outcomes and community engagement are guiding the implementation of expanding population-based carrier screening in Singapore, contingent on addressing practical challenges through equitable outreach and professional training.
- 6 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-3
MAGIC: an international network for evaluating generative artificial intelligence in global health
- 6 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-3
MAGIC: an international network for evaluating generative artificial intelligence in global health
- 11 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3534-3538
A global digital navigator of human health for precision medicine
- 11 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3534-3538
A global digital navigator of human health for precision medicine
- Open Access
- 7 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Telomere variant sequences encode the genetic blueprint for allele-specific telomere length
The ends of human chromosomes are capped by specialized nucleoprotein structures, termed telomeres, which are essential for genome stability. Recent advances in long-read sequencing have enabled allele-specific telomere length measurements at nucleotide resolution, uncovering extreme heterogeneity in telomere length between alleles. The progressive telomere shortening over time makes steady-state telomere length in human somatic cells a promising biomarker for age-associated diseases. However, the mechanisms underlying allele-specific telomere maintenance and its stability remain poorly understood. Here, we developed a high-resolution workflow combining PacBio and Nanopore long-read sequencing platforms to map allele-specific telomere length in human blood samples as well as cultured cell lines. By tracing allele-specific telomeric sequence in family members across multiple generations, we show that the allele-specific telomeric variant sequences (TVSs) are heritable and underlie the extreme heterogeneity of telomere length between alleles. Continuous cell proliferation likely drives the slow but stochastic evolution of allele-specific TVSs, resulting in asymmetry in telomere inheritance from father and mother (p-value = 2.354e-7). Targeted deletion of allele-specific TVSs using CRISPR-Cas9 resets telomere length, further confirming their causal role in the control of allele-specific telomere maintenance. These results indicated that TVSs are heritable genetic elements underlying the allele-specific telomere length.
- 7 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTelomere variant sequences encode the genetic blueprint for allele-specific telomere length
The ends of human chromosomes are capped by specialized nucleoprotein structures, termed telomeres, which are essential for genome stability. Recent advances in long-read sequencing have enabled allele-specific telomere length measurements at nucleotide resolution, uncovering extreme heterogeneity in telomere length between alleles. The progressive telomere shortening over time makes steady-state telomere length in human somatic cells a promising biomarker for age-associated diseases. However, the mechanisms underlying allele-specific telomere maintenance and its stability remain poorly understood. Here, we developed a high-resolution workflow combining PacBio and Nanopore long-read sequencing platforms to map allele-specific telomere length in human blood samples as well as cultured cell lines. By tracing allele-specific telomeric sequence in family members across multiple generations, we show that the allele-specific telomeric variant sequences (TVSs) are heritable and underlie the extreme heterogeneity of telomere length between alleles. Continuous cell proliferation likely drives the slow but stochastic evolution of allele-specific TVSs, resulting in asymmetry in telomere inheritance from father and mother (p-value = 2.354e-7). Targeted deletion of allele-specific TVSs using CRISPR-Cas9 resets telomere length, further confirming their causal role in the control of allele-specific telomere maintenance. These results indicated that TVSs are heritable genetic elements underlying the allele-specific telomere length.
- 18 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2411
Publisher Correction: Translating genomic data into healthcare practice with the Singapore National Precision Medicine program
- 18 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2411
Publisher Correction: Translating genomic data into healthcare practice with the Singapore National Precision Medicine program